Aptahem

Executive Summary

Aptahem is a Swedish biotechnology company developing an emergency treatment for sepsis, a life-threatening condition that claims millions of lives globally each year. The company's lead candidate, AHA-3, is a nucleic acid-based aptamer designed to modulate the inflammatory response and prevent organ failure. With a focus on the critical first hours of sepsis, Aptahem aims to address the urgent need for therapies that can be administered rapidly to reduce mortality. The company is currently in the preclinical stage, having demonstrated promising results in animal models, including improved survival and reduced organ damage. Aptahem's innovative approach targets the coagulation and immune systems, offering a novel mechanism of action distinct from existing antibiotics and supportive care. The company is based in Malmö, Sweden, and has a strong intellectual property portfolio covering its aptamer technology. Looking ahead, Aptahem is poised to advance its lead candidate into clinical development. The company is actively seeking partnerships and funding to support a first-in-human trial. Key upcoming milestones include the completion of toxicology studies, manufacturing scale-up, and regulatory interactions to enable an IND/CTA filing. With sepsis being a major global health burden, Aptahem's potential to provide an effective emergency treatment could address a large unmet medical need. However, the preclinical stage and challenging clinical trial landscape for sepsis indicate significant risk. The company's success hinges on demonstrating safety and efficacy in humans, securing sufficient capital, and navigating regulatory pathways.

Upcoming Catalysts (preview)

• Q4 2026Completion of GLP Toxicology Studies75% success
• Q2 2027IND/CTA Filing for First-in-Human Trial50% success
• H2 2027Partnership or Licensing Deal40% success